- Abbott Laboratories (NYSE:ABT) reported strong one year VERITAS trial outcomes for its investigational Amulet 360 Left Atrial Appendage Occluder in non valvular atrial fibrillation patients.
- The company highlighted high appendage closure rates and a low incidence of complications in the pivotal study cohort.
- Amulet 360, which has CE mark approval in Europe, remains under FDA review for use in the United States.
- These Amulet 360 VERITAS results matter, but investors should weigh them alongside Abbott's broader risks and fundamentals. We have also flagged 3 warning signs for Abbott Laboratories.
For a wider view on how medical technology and data are changing treatment and diagnostics, consider exploring 34 healthcare AI stocks.
Abbott Laboratories is a large medical equipment group headquartered in GB that develops and sells health care products worldwide. An atrial fibrillation device like Amulet 360 fits directly into its broader push to serve cardiology and hospital customers with specialized hardware.
2 things going right for Abbott Laboratories that this headline doesn't cover.
What Amulet 360’s data really shifts in the Abbott Laboratories story
The VERITAS results give Abbott Laboratories fresh evidence for one of the key Narrative catalysts: the push to grow electrophysiology and structural heart devices as a larger earnings driver. Strong closure and safety figures from Amulet 360 reinforce the idea that Abbott’s atrial fibrillation toolkit, alongside Volt and TactiFlex Duo, can support procedure volumes and help balance Nutrition related legal and margin pressures highlighted in the Narrative. The read across is clearest for that electrophysiology and structural heart catalyst, not for broader earnings or balance sheet risks yet.
See how these catalysts shape Abbott Laboratories' path to a $120 fair value.
For this update to influence how investors think about Abbott Laboratories in a lasting way, the next checkpoints are concrete regulatory and adoption milestones. Watch for the U.S. FDA decision on Amulet 360, any early procedure volume disclosures where the device is already approved, and how management frames atrial fibrillation contributions within the broader devices and diagnostics segment in upcoming earnings calls.
Add Abbott Laboratories to your Watchlist and get alerts as these catalysts play out.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com